// App-Quantinova.ai

: Efficacy and Safety of Dabigatran Etexilate for Treatment of Venous Thromboembolism in Paediatric Patients ‐ Results of the DIVERSITY Trial

Researchers

Presenter

  • M. Albisetti

Principal Investigators

  • L. Brandao

  • L. Bomgaars

  • E. Chalmers

  • M. Luciani

  • L. Mitchell

  • I. Nurmeev

  • P. Svirin

  • T. Kuhn

  • O. Zapletal

  • I. Tartakovsky

  • M. Simetzberger

  • S. Wiebe

  • Z. Sun

  • S. Gropper

  • M. Brueckmann

  • J. Halton

Medical Centers

  • University Childrens Hospital, Zurich, Switzerland

  • Hospital for Sick Children, Toronto, ON, Canada

  • Texas Children's Cancer Center, Baylor College of Medicine, Department of Pediatrics, Houston, United States

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Pediatric Hospital Bambino Gesù, Pediatric Hematology/Oncology, Rome, Italy

  • Pediatric Hospital, Kazan, Republic Tatarstan, Russian Federation

  • Morozovskaya Children Hospital, Pediatric Hematology, Moscow, Russian Federation

  • University Hospital Ostrava, Pediatric Hematology/Oncology, Ostrava‐ Poruba, Czech Republic

  • University Hospital Brno, Pediatric Hematology, Brno, Czech Republic

  • Boehringer Ingelheim International GmbH, Therapeutic Area Cardiovascular Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim RCV GmbH & Co. KG, Department of Clinical Development, Wien, Austria

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine and Clinical Pharmacology, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim Pharmaceuticals, Inc, Translational Medicine and Clinical Pharmacology, Ridgefield, United States

  • Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada,

Locations

  • Switzerland

  • Canada

  • United States

  • United Kingdom

  • Italy

  • Russia

  • Czech Republic

  • Germany

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

  • Pradax

  • Heparin

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved